Low
₹498.00
High
₹513.00
| Previous Close | ₹510.80 |
|---|---|
| Day's Range | ₹498.00 - ₹513.00 |
| Open | ₹505.90 |
| 52 Week Range | ₹422.00 - ₹734.40 |
| Volume | 43,877 |
| Market Cap | ₹0.00 |
| Previous Close | ₹511.25 |
|---|---|
| Day's Range | ₹499.05 - ₹513.40 |
| Open | ₹502.30 |
| 52 Week Range | ₹422.85 - ₹734.20 |
| Volume | 1,933 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 224.12 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -3.97 |
| P/E Ratio | 3820.42 |
| Book Value(₹) | 1.95 |
| PAT Margin (%) | 0.04 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 6.07 |
| Trade Value ( ₹ in Lacs) | 9.88 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -3.97 |
| P/E Ratio | 3820.42 |
| Book Value(₹) | 1.95 |
| PAT Margin (%) | 0.04 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 6.07 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 3003.1 | 12889.2 |
| Expenses | N/A | N/A |
| PBT | 81.0 | -4884.2 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 81.0 | -5669.6 |
| Founded | 2017 |
|---|---|
| Managing Director | Sandeep Rao |
| NSE Symbol | SOLARA |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,36,858.91 | 1,836.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,76,617.57 | 6,677.90 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,44,717.58 | 4,328.75 | 3,101.60 - 3,101.60 |
| Apollo Hospitals Enterprise Ltd. | 1,11,737.93 | 7,765.10 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,07,721.85 | 1,356.50 | 1,165.70 - 1,165.70 |
| Lupin Ltd. | 1,07,143.97 | 2,416.05 | 1,836.80 - 1,836.80 |
| Dr. Reddy's Laboratories Ltd. | 1,06,080.73 | 1,293.90 | 1,129.40 - 1,129.40 |
| Max Healthcare Institute Ltd. | 97,300.05 | 1,014.05 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 95,803.01 | 2,336.05 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 91,753.45 | 931.75 | 835.50 - 835.50 |
No Records Found
Solara Active Pharma Sciences has informed that the Meeting of the Rights Issue Committee of the Board of Directors of the Company held today, Tuesday, March 24, 2026 has considered and approved the making of Second & Final call of ₹ 112.50/- per equity shares (₹ 3.00/- towards face value and ₹ 109.50/- towards securities premium) per Rights Share in respect of partly-paid Rights Shares, on Rights basis, pursuant to the Letter of Offer dated May 09, 2024. Rights Issue Committee has fixed Thursday, April 02, 2026, as the Record date for the purpose of determining the holders of partly paid-up Equity Shares to whom the call notice will be dispatched for payment of the call. Details under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been enclosed as Annexure I. The Rights Issue Committee Meeting commenced at 9.30 am and concluded at 9.55 am.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Solara Active Pharma Sciences has informed that the Board of Directors of the Company at their meeting held today, February 06, 2026, have considered and approved the following matters: 1. Amended the ‘Policy for Determining Materiality of Events / Information for Disclosure to Stock Exchanges’ in line with the amendments in Regulation 30 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015. The amended Policy is available on the Company’s website at solara.co.in/investor-relations/policies-and-guidelines/. 2.The Members of the Board has reviewed and adopted the revised ‘Policy for Governance of Related Party Transactions’ in compliance with amendment to the Regulation 23 of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015 and any amendments thereto. The amended Policy is available on the Company’s website at solara.co.in/investor-relations/policies-and-guidelines/.
The above information is a part of company’s filings submitted to BSE.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 168.53 | 140.69 | 19.79 | 699.34 | 671.92 | 4.08 | 699.34 | 671.92 | 4.08 |
| Other Income | 3.65 | 0.69 | 428.99 | 4.44 | 1.68 | 164.29 | 4.44 | 1.68 | 164.29 |
| PBIDT | 9.38 | 5.17 | 81.43 | 34.43 | 29.30 | 17.51 | 34.43 | 29.30 | 17.51 |
| Interest | 0.26 | 0.26 | 0.00 | 1.12 | 1.03 | 8.74 | 1.12 | 1.03 | 8.74 |
| PBDT | 9.12 | 4.91 | 85.74 | 33.31 | 28.27 | 17.83 | 33.31 | 28.27 | 17.83 |
| Depreciation | 1.65 | 1.48 | 11.49 | 6.77 | 6.71 | 0.89 | 6.77 | 6.71 | 0.89 |
| PBT | 7.47 | 3.43 | 117.78 | 26.54 | 21.56 | 23.10 | 26.54 | 21.56 | 23.10 |
| TAX | 7.04 | 0.16 | 4300.00 | 8.89 | 6.07 | 46.46 | 8.89 | 6.07 | 46.46 |
| Deferred Tax | 1.64 | -0.58 | -382.76 | 1.04 | 0.18 | 477.78 | 1.04 | 0.18 | 477.78 |
| PAT | 0.43 | 3.27 | -86.85 | 17.65 | 15.49 | 13.94 | 17.65 | 15.49 | 13.94 |
| Equity | 96.61 | 96.61 | 0.00 | 96.61 | 96.61 | 0.00 | 96.61 | 96.61 | 0.00 |
| PBIDTM(%) | 5.57 | 3.67 | 51.46 | 4.92 | 4.36 | 12.90 | 4.92 | 4.36 | 12.90 |
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 12105.30 | 10139.40 | 19.39 | 48459.20 | 43220.40 | 12.12 | 48459.20 | 43220.40 | 12.12 |
| Other Income | 629.80 | 179.30 | 251.25 | 2044.00 | 1198.70 | 70.52 | 2044.00 | 1198.70 | 70.52 |
| PBIDT | 3010.30 | 2675.80 | 12.50 | 14023.90 | 13245.90 | 5.87 | 14023.90 | 13245.90 | 5.87 |
| Interest | -7.40 | 6.70 | -210.45 | 25.90 | 46.00 | -43.70 | 25.90 | 46.00 | -43.70 |
| PBDT | 3017.70 | 2669.10 | 13.06 | 13998.00 | 13199.90 | 6.05 | 13998.00 | 13199.90 | 6.05 |
| Depreciation | 441.60 | 387.60 | 13.93 | 1687.70 | 1399.30 | 20.61 | 1687.70 | 1399.30 | 20.61 |
| PBT | 2576.10 | 2281.50 | 12.91 | 12310.30 | 11800.60 | 4.32 | 12310.30 | 11800.60 | 4.32 |
| TAX | 603.30 | 347.20 | 73.76 | 2842.10 | 2631.70 | 7.99 | 2842.10 | 2631.70 | 7.99 |
| Deferred Tax | -70.00 | -43.80 | 59.82 | 76.00 | 51.40 | 47.86 | 76.00 | 51.40 | 47.86 |
| PAT | 1972.80 | 1934.30 | 1.99 | 9468.20 | 9168.90 | 3.26 | 9468.20 | 9168.90 | 3.26 |
| Equity | 250.70 | 250.70 | 0.00 | 250.70 | 250.70 | 0.00 | 250.70 | 250.70 | 0.00 |
| PBIDTM(%) | 24.87 | 26.39 | -5.77 | 28.94 | 30.65 | -5.57 | 28.94 | 30.65 | -5.57 |
No Records Found
The current share price of Solara Active Pharma Sciences Ltd. is ₹510.80 as of 2026-05-06.
The market capitalisation of Solara Active Pharma Sciences Ltd. is ₹2,417.25 as of 2026-05-05.
The 1-year return of Solara Active Pharma Sciences Ltd. is 9.60% as of 2026-05-06.
The P/E ratio of Solara Active Pharma Sciences Ltd. is 3820.42 as of 2026-05-06.
The 52-week high and low of Solara Active Pharma Sciences Ltd. are ₹734.40 and ₹422.00, respectively, as of 2026-05-06.
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.